Pressmeddelanden

Founders Alliance presenterar Juryledamöterna Founders Awards 2020

Founders Alliance presenterar Juryledamöterna Founders Awards 2020

2020-09-21 13:44 CEST
För att utse vinnarna av Founders Alliance pris Årsringarna i guld och silver på torsda...

​Värmevärdens ägare förvärvar Adven

2020-09-21 09:40 CEST
Värmevärdens ägare har tecknat avtal om att förvärva 100 procent av aktierna i Adven, e...

Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer

Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer

2020-09-21 08:08 CEST
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisat...

Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

2020-09-21 08:02 CEST
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisat...

Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in PROfound Phase III trial

Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in PROfound Phase III trial

2020-09-20 18:33 CEST
Final results from the PROfound Phase III trial showed AstraZeneca and MSD’s Lynparza (...

Tagrisso reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage EGFR-mutated lung cancer

Tagrisso reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage EGFR-mutated lung cancer

2020-09-20 18:30 CEST
Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial...

NORRLANDSFONDEN INVESTERAR I HEMMONITORERING

NORRLANDSFONDEN INVESTERAR I HEMMONITORERING

2020-09-18 15:57 CEST
NORRLANDSFONDEN INVESTERAR I HEMMONITORERING Deversify AB meddelar att bolaget kommit ö...

Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years

Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years

2020-09-18 09:16 CEST
Updated results from the PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalum...

Byggstart för Gavlegårdarnas hållbara  hus i Godisfabriken

Byggstart för Gavlegårdarnas hållbara hus i Godisfabriken

2020-09-16 14:47 CEST
Nu går startskottet för Gavlegårdarnas bygge av de två hus med träfasad av som blir por...